secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001437749-24-015453
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q1 net loss $1.6M; pivots to radiopharma pipeline, winding down other programs
--------------------------------------------------------------------------------

- Net loss $1.6M ($0.10/shr) vs $2.4M ($0.19/shr) in Q1 2023.
- Cash and short-term investments $8.8M as of Mar 31, 2024, sufficient through June 2025.
- Company winding down non-radiopharma programs (camsirubicin, MNPR-202) to focus on MNPR-101 radiopharma.
- First-in-human Phase 1 trial of MNPR-101-Zr initiated; targeting MNPR-101-RIT Phase 1 launch by Q4 2024/Q1 2025.
- Additional funding will be needed within the next 12 months to support operations beyond current runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/0001437749-24-015453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924015453/mnpr20240502_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer